AVLN NASDAQ
Avalyn Pharma Inc. Common Stock
1W: -3.5%
1M: -4.7%
YTD: -6.3%
$27.79
+0.17 (+0.62%)
Weekly Expected Move ±10.6%
$22
$25
$28
$31
$34
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.2B
52W Range24.15-33.32
Volume183,860
Avg Volume496,254
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLyn Baranowski
Employees50
SectorHealthcare
IndustryBiotechnology
IPO Date2026-04-30
Websiteavalynpharma.com
105 W First St. Boston
Boston, MA 02127
US
Boston, MA 02127
US
1-206-707-0340
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Latest News
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Catalyst Watch: Fedspeak ramps up post-Powell, core PCE, and box office blitz
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
AVLN SEC Filings - AVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Recent Insider Trades
No insider trades found